secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001178913-25-000857
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio-OPKO collaboration: oral GLP-1/glucagon tablet, $8M equity investment
--------------------------------------------------------------------------------

- OPKO purchased 3,685,226 Entera shares at ~$2.17/share ($8M) to fund Entera's 40% development cost share through Phase 1.
- Profit/cost split initially 60% OPKO / 40% Entera; opt-out after Phase 1 yields 85%/15% with OPKO funding.
- Parties expect to file IND with FDA later in 2025 for oral tablet combining OPK-88006 and Entera's N-Tab™ technology.
- OPKO subject to 12-month lockup on shares and 24-month standstill on acquiring additional Entera equity.
- Preclinical data reported September 2024 showed favorable pharmacodynamic and pharmacokinetic profiles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/0001178913-25-000857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/zk2532871.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-000857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer